Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
- 10 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.